West Pharmaceutical Services layoffs, on the record
Every job cut, severance charge and restructuring West Pharmaceutical Services reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 10,600 to approximately 10,800.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 10,600 | As of December 31, 2023 |
| 10-K for 2024 | approximately 10,600 | As of December 31, 2024 |
| 10-K for 2025 | approximately 10,800 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryRecorded a benefit to restructuring and other charges of $2.8 million for revised severance estimates under the 2022 restructuring plan, which together with an inventory write-down gave a net $2.0 million benefit.
Word for word“During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million benefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold.” 10-K for 2023
Our summaryCarried out a 2022 restructuring plan to adjust the operating cost base, including severance, post-employment benefits and asset-related charges.
Word for word“During 2022, the Company recorded expense to restructuring and other charges of $23.8 million, which primarily included a charge of $8.7 million in net severance and post-employment benefits primarily in connection with our plan to adjust our operating cost base and $15.3 million in asset-related charges associated with this plan.” 10-K for 2023
Our summaryRecorded expense to optimize certain organizational structures.
Word for word“During 2021, the Company recorded expense to restructuring and other charges of $2.2 million to optimize certain organizational structures within the Company.” 10-K for 2023
Our summaryRecorded restructuring and other charges in 2024, including a plan to optimize the legal structure of the Company and its subsidiaries, partly offset by revised severance estimates tied to the 2022 restructuring plan.
Word for word“During 2024, the Company recorded expense to restructuring and other charges of $2.1 million.” 10-K for 2024
Our summaryRecorded a benefit to restructuring and other charges in 2023, reflecting revised severance estimates for the 2022 restructuring plan and an inventory write down.
Word for word“During 2023, the Company recorded a benefit to restructuring and other charges of $2.0 million, which represents the net impact of a $2.8 million b enefit within other expense (income) for revised severance estimates in connection with its 2022 restructuring plan and an inventory write down of $0.8 million within cost of goods and services sold.” 10-K for 2024
Our summaryCarried a remaining balance for restructuring and severance related charges within other current liabilities.
Word for word“Restructuring and severance related charges 1.6 3.8 Accrued interest 1.6 2.6 Other 39.9 37.4 Total other current liabilities $ 188.2 $ 155.2 Note 10: Debt The following table summariz” 10-K for 2024
Our summaryThe company recorded charges for severance, accelerated depreciation and lease costs under its January 2025 restructuring plan, plus professional fees for a plan to optimize its legal structure.
Word for word“(1) During 2025, the Company recorded pre-tax charges of $23.3 million related to our two existing restructuring programs: (i) $18.4 million within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $4.9 million within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries.” 10-K for 2025
Our summaryThe company recorded severance and lease impairment charges tied to its agreement to sell the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie.
Word for word“The Company recorded $6.2 million of the charges within other expense (income), related to severance and lease impairment charges in connection with the sale agreement.” 10-K for 2025
Our summaryThe company recorded a net benefit in 2024 from revised severance estimates on its 2022 restructuring plan, offset by legal-structure optimization costs.
Word for word“This expense was partially offset by a $2.5 million benefit recorded within other expense (income) related to revised severance estimates in connection with the Company's 2022 restructuring plan.” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges | Restructuring costs incurred | Cash paid for restructuring |
|---|---|---|---|---|
| 2016-12-31 | $8.9 million | $26.4 million | $26.4 million | $3 million |
| 2017-12-31 | $0 | — | $0 | $3.1 million |
| 2018-12-31 | $3.1 million | — | $9.1 million | — |
| 2019-12-31 | $2.6 million | — | $4.9 million | — |
| 2020-12-31 | $4.6 million | — | $4.6 million | — |
| 2021-12-31 | $600,000 | — | $2.2 million | — |
| 2022-12-31 | $8.7 million | — | $23.8 million | — |
| 2023-12-31 | −$2.8 million | — | −$2.8 million | — |
| 2024-12-31 | −$2.5 million | — | −$2.5 million | — |
| 2025-12-31 | $19.2 million | — | $24.6 million | $0 |
West Pharmaceutical Services filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from West Pharmaceutical Services’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.